Is single-inhaler triple therapy for COPD cost-effective in the UK? The IMPACT trial

BACKGROUND: The IMPACT trial demonstrated superior outcomes following 52 weeks of once-daily single-inhaler treatment with fluticasone furoate (FF)/umeclidinium (UMEC)/vilanterol (VI) (100/62.5/25 μg) compared with once-daily FF/VI (100/25 μg) or UMEC/VI (62.5/25 μg). This study evaluated the cost-e...

Descripción completa

Detalles Bibliográficos
Autores principales: Martin, Alan, Shah, Dhvani, Ndirangu, Kerigo, Anley, Glenn A., Okorogheye, Gabriel, Schroeder, Melanie, Risebrough, Nancy, Ismaila, Afisi S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2022
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8859506/
https://www.ncbi.nlm.nih.gov/pubmed/35198630
http://dx.doi.org/10.1183/23120541.00333-2021

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8859506/
https://www.ncbi.nlm.nih.gov/pubmed/35198630
http://dx.doi.org/10.1183/23120541.00333-2021

Ejemplares similares